NCT00003512 - Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Waldenstrom's Macroglobulinemia | Biotech Hunter

Timeline

Start Date

February 18, 1999

Primary Completion Date

April 26, 2000

Study Completion Date

April 26, 2000

Conditions

Waldenstrom Macroglobulinemia

Interventions

DRUG

Antineoplaston therapy (Atengenal + Astugenal)

"Patients With Recurrent or Refractory Waldenstrom's Macroglobulinemia will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."

Trial Locations (1)

77055-6330

Burzynski Clinic, Houston